Reata common stock offering
13 Nov 2019 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. public offering of 2400000 shares of its Class A common stock at a price to the 18 Nov 2019 Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares. Email Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters' Option to Purchase Additional 12 Nov 2019 Reata Pharma (RETA) Announces 2M Share Proposed Public Offering of Class A Common Stock. Article Related Press Releases (2) Related We are selling shares of Class A common stock in this offering. We currently expect the initial public offering
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters' Option to Purchase Additional
The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. The offering closed on November 18, 2019. The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. Citigroup , Jefferies, SVB Leerink and Stifel acted as the joint book-running managers for the offering. PLANO, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $183.00 per share. IRVING, Texas, July 24, 2018 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 3,000,000 shares of its Class A common stock at a price to the public of $72.00 per share. PLANO, Texas, Nov 13, 2019 (GLOBE NEWSWIRE via COMTEX) -- Reata Pharmaceuticals, Inc. RETA, -0.15% ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share. The offering was upsized to 2,400,000 shares from the original offering size of 2,000,000 shares.
PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share. The offering was upsized to 2,400,000 shares from the original offering size of 2,000,000 shares.
Ladenburg Thalmann & Co. Inc. is acting as co-manager for the offering. Reata intends to grant the underwriters a 30-day option to purchase up to 450,000 additional shares of its Class A common stock, on the same terms and conditions as the shares offered in the public offering. 12 November 2019 Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell PLANO, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their
PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Reata Pharmaceuticals, Inc. Announces
1 Jun 2016 Read about Reata Pharmaceuticals' IPO, and its plans to advance its initial public offering of 5,500,000 shares of its Class A common stock at
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Reata Pharmaceuticals, Inc. Announces PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an
The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. The offering closed on November 18, 2019. The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. Citigroup , Jefferies, SVB Leerink and Stifel acted as the joint book-running managers for the offering. PLANO, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $183.00 per share. IRVING, Texas, July 24, 2018 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 3,000,000 shares of its Class A common stock at a price to the public of $72.00 per share. PLANO, Texas, Nov 13, 2019 (GLOBE NEWSWIRE via COMTEX) -- Reata Pharmaceuticals, Inc. RETA, -0.15% ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the PLANO, Texas, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share. The offering was upsized to 2,400,000 shares from the original offering size of 2,000,000 shares.